Repare Therapeutics 주식 (NASDAQ: RPTX)

Repare Therapeutics (NASDAQ:RPTX) 주식

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

Equities

News

Markets

ETFs

ARKF

ARKG

ARKK

ARKW

CDNA

GTLB

IBTA

NTLA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

Repare Therapeutics Inc

Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading higher Monday following reports that incoming CEO Lip-Bu Tan is preparing a sweeping overhaul of the company's chip design, manufacturing <a href="https://www.benzinga.com/25/03/44355124/intels-new-ceo-charts-bold-revival-plan-warns-of-tough-decisions-ahead-reports">operations and AI strategy.</a>
What To Know: According to Reuters, Tan's plan includes cost-cutting measures, a restructuring of management and a renewed focus on AI chip production. Tan, who was previously a board member and CEO of chip design software firm Cadence, is stepping in after Intel's years of missteps under multiple CEOs. 
He has been openly critical of former CEO Pat Gelsinger's execution, particularly in manufacturing and decision-making. One of Tan's key priorities is revamping Intel Foundry, which produces chips for companies like Microsoft and Amazon. He is also expected to restart AI initiatives beyond servers, including software, robotics and AI foundation models.
Intel has struggled to compete with industry leaders such as Nvidia and Taiwan Semiconductor Manufacturing Co. (TSMC). Under Gelsinger, Intel aimed to establish itself as a major contract chip manufacturer but execution problems and a weakening market forced cutbacks. Tan's strategy involves securing large customers for Intel's foundry business while improving manufacturing efficiency. 
Despite an annual loss of $19 billion in 2024, Intel's financial outlook is tied to the success of its next-generation AI chips, known as Panther Lake, which will rely on the company's new 18A manufacturing process. Tan is expected to push for an annual release schedule of AI chips to compete with Nvidia, though industry experts estimate it will take years before Intel can produce a truly competitive AI architecture.
At an internal town hall, Tan acknowledged the need for "tough decisions" as he looks to streamline operations. His approach marks a significant shift in leadership style, with a focus on aggressive restructuring and efficiency. 
INTC Price Action: Intel shares were up 7.92% at $25.95 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131554/Screenshot-2025-03-17-at-13.15.25-1024x524.png" alt="" class="wp-image-827815" style="width:440px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131554/Screenshot-2025-03-17-at-13.15.25-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131554/Screenshot-2025-03-17-at-13.15.25-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131554/Screenshot-2025-03-17-at-13.15.25-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131554/Screenshot-2025-03-17-at-13.15.25.png 1528w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44360400/legendary-trader-says-tesla-nvidia-apple-shares-are-ready-to-rally-i-see-what-i-like-to-see">Legendary Trader Says Tesla, Nvidia, Apple Shares Are Ready To Rally: &#8216;I See What I Like To See&#8217;</a></li>
</ul>
Image Via Shutterstock.

Movers

INTC

Intel Shares Surge As New CEO Plans Major Overhaul: What's Going On?

JP Morgan analyst Arun Jayaram reiterated an Underweight rating on ProFrac Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) <a target="_blank" href="https://www.benzinga.com/quote/acdc/analyst-ratings" rel="noreferrer noopener">with a price forecast of $7</a>.
On March 6, the company reported fourth-quarter sales of $454.7 million, which missed the consensus of&nbsp;$479.3 million and reported net loss of&nbsp;$105.0 million vs. a loss of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44160592/profrac-holding-corp-reports-full-year-and-fourth-quarter-2024-results" rel="noreferrer noopener">$45.2 million a year ago quarter</a>.
The analyst writes that the results showed EBITDA and FCF misses due to seasonality and a weaker macro environment.
Management highlighted an increase in ACDC&#8217;s active fleet count, which has reached its highest level since mid-2024, with six additional fleets secured since the fourth-quarter low point, adds the analyst.
Jayaram notes that the company anticipates the lower average pricing to offset modestly higher activity in Stimulation Services year-over-year.
Also, the company expects continued industry-wide equipment attrition due to higher hours pumped per fleet and lower reinvestment levels, adds the analyst.
The analyst estimates 29.3 average fleets in the first quarter of 2025, resulting in Stimulation Services EBITDA (~$10.9 million annualized EBITDA/fleet) of $80 million.
Jayaram anticipates that the company&#8217;s profitability will improve as utilization increases across its business units throughout the year, although at a slower pace.
Consequently, the analyst revised the 2025-26 EBITDA forecast to $472 million and $588 million, down from $543 million and $680 million, respectively.
Also, the analyst sees 2025-26 FCF generation of $78 million and $184 million, respectively and capital expenditure of $340 million and $447 million, respectively.
Investors can gain exposure to the stock via&nbsp;Invesco Oil &amp; Gas Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PXJ#NYSE">PXJ</a>).
Price Action: ACDC shares are down 1.65% at $7.15 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44357988/zoom-introduces-customizable-ai-companion-with-new-add-ons-for-businesses" target="_blank" rel="noreferrer noopener">Zoom Introduces Customizable AI Companion With New Add-Ons For Businesses</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Reiteration

Small Cap

Analyst Ratings

Trading Ideas

ACDC

PowerShares Exchange-Traded Fund Trust Dynamic Oil Services Portfolio

JPMorgan Cuts ProFrac's Earnings Forecast On Lower Reinvestment And Industry Attrition

Macro Economic Events

Global

Economics

TSLA

Honda, Suzuki To Join Tesla Carbon Emissions Pool For 2025 To Comply With EU 2025 Rules

Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) released on Monday del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy amenable to <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">exon 44 skipping (DMD44)</a>.
Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal and cardiac muscle tissue to specifically skip exon 44 of the dystrophin gene and enable the production of near-full-length dystrophin.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44286904/dyne-therapeutics-4-3-billion-peak-sales-potential-analyst-highlights-key-strengths-and-risks" rel="noreferrer noopener">Dyne Therapeutics&#8217; $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks</a>
The data presented highlighted the consistent data across all parameters in both the 5 mg/kg and 10 mg/kg cohorts of <a href="https://www.benzinga.com/pressreleases/25/03/n44352786/avidity-biosciences-announces-positive-topline-del-zota-data-demonstrating-consistent-statisticall" target="_blank" rel="noreferrer noopener">del-zota, including</a>:
<ul>
<li>Targeted delivery of PMOs resulting in tissue concentrations of approximately 200nM in skeletal muscle;</li>
<li>Statistically significant increases of approximately 40% in exon 44 skipping.</li>
<li>Statistically significant increase of approximately 25% of normal in dystrophin production and restored total dystrophin up to 58% of normal.</li>
<li>Reduction in creatine kinase levels to near normal with greater than 80% reductions compared to baseline:
<ul>
<li>Similarly, placebo participants demonstrated a reduction in creatine kinase levels to near normal upon treatment with del-zota.</li>
<li>Significant reductions in creatine kinase levels were sustained in the EXPLORE44-OLE trial with continued treatment up to one year.</li>
</ul>
</li>
<li>Del-zota demonstrated favorable safety and tolerability at both doses, with most treatment emergent adverse events (TEAEs) mild or moderate.</li>
</ul>
Based on the consistent data between the 5 mg/kg every six weeks and the 10mg/kg every eight weeks groups across all parameters, Avidity has selected the dose of 5 mg/kg every six weeks of del-zota for the Biologics License Application (BLA) submission and future clinical studies.
Participants receiving the 10 mg/kg dose in the EXPLORE44-OLE trial are being transitioned to 5 mg/kg every six weeks.&nbsp;
The company plans to present functional data in the fourth quarter of 2025 and is on track for a BLA submission by the end of 2025 for accelerated approval of 5 mg/kg of del-zota every six weeks in DMD44.
Following alignment with the FDA on the accelerated approval path late last year, including dose selection, Avidity&#8217;s commercial preparations for a potential U.S. launch of del-zota in DMD44 are well underway.
RNA Price Action: Avidity Biosciences stock is up 6.56% at $33.15 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44357988/zoom-introduces-customizable-ai-companion-with-new-add-ons-for-businesses" target="_blank" rel="noreferrer noopener">Zoom Introduces Customizable AI Companion With New Add-Ons For Businesses</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025

Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) is on the verge of forming <a href="https://www.benzinga.com/topic/golden-cross">a Golden Cross</a> — a bullish technical signal that occurs when the 50-day simple moving average (SMA) rises above the 200-day SMA.
While the stock has been in a downtrend, falling nearly 19% in the past month, buying pressure is beginning to emerge. This shift in momentum suggests Pinterest stock could be setting up for a bullish breakout.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="618" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131914/Screenshot-2025-03-17-at-5.06.54-PM.png" alt="" class="wp-image-827824" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131914/Screenshot-2025-03-17-at-5.06.54-PM.png 618w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17131914/Screenshot-2025-03-17-at-5.06.54-PM-300x236.png 300w" sizes="(max-width: 618px) 100vw, 618px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Read Also: <a href="https://www.benzinga.com/general/social-media/25/02/43552113/pinterests-ai-taste-graph-expands-75-as-meta-rival-hits-first-1-billion-revenue-quarter">Pinterest&#8217;s AI &#8216;Taste Graph&#8217; Expands 75% As Meta-Rival Hits First $1 Billion Revenue Quarter</a>
<h2 class="wp-block-heading">Pinterest Stock's Golden Cross Could Signal A Bullish Turn</h2>
Despite recent weakness, key technical signals point toward a potential turnaround:
<ul>
<li>Golden Cross Formation: The 50-day SMA is on track to cross above the 200-day SMA, a historically bullish pattern.</li>
<li>Buying Pressure Emerging: While Pinterest's stock is still trading below its eight-day, 20-day, and 50-day SMAs, growing demand could push prices higher.</li>
<li>Moving Average Convergence Divergence (MACD): Currently at a negative 0.89, the MACD remains in bearish territory but is trending higher, suggesting a shift in momentum.</li>
<li>Relative Strength Index (RSI): At 39.99, RSI is approaching neutral territory, indicating that selling pressure is fading.</li>
</ul>
With these technicals improving, Pinterest may be gearing up for a bullish breakout.
<h2 class="wp-block-heading">Investor Implications: A Bullish Setup In The Making?</h2>
A golden cross is often seen as a strong bullish indicator, suggesting the potential for a sustained rally. While Pinterest's recent weakness has weighed on sentiment, increasing buying pressure could signal a shift in trend.
Investors watching for confirmation may wait for the golden cross to officially form, but the improving technical backdrop suggests Pinterest's stock could be on the verge of a rebound. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44357674/restaurant-sales-sink-recession-warning-or-just-weather-driven-dip">Restaurant Sales Sink: Recession Warning Or Just Weather-Driven Dip?</a></li>
</ul>
Image: Shutterstock

Social Media

Technicals

Signals

Tech

PINS

Pinterest Stock Poised For A Golden Cross, Time To Go Bullish?

Looking into the current session, Western Alliance Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) shares are trading at $77.00, after a 0.31% drop. Over the past month, the stock decreased by 15.99%, but over the past year, it actually increased by 32.32%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1742233522_0.png" alt="Past Year Chart" />

<h3>Western Alliance P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 15.08 in the Banks industry, Western Alliance Inc. has a lower P/E ratio of 10.89. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1742233522_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Western Alliance Inc's Price Over Earnings

Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) ahead of its first Investor Day as a public company on March 19.
The analyst reiterated the Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/verx/analyst-ratings" rel="noreferrer noopener">price forecast of $48.</a>
Hotchkiss expects that management will highlight how the company is largely shielded from broader macroeconomic uncertainty due to the critical role of tax software in the current landscape.
The analyst also expects them to provide further insight into the sustainability of mid-teens or higher revenue growth in the medium term.
In particular, the analyst anticipates that management will focus on addressing several key points, including the sustainability of demand and market dynamics within the broader enterprise tax software market.
Also, Hotchkiss expects to learn about the importance of e-invoicing and international expansion in driving future revenue growth at the investor day.
Additionally, the analyst anticipates getting clarity on the future investment roadmap and the monetization of new product initiatives.
Finally, the analyst expects to know about the impact of these investments and scale-driven efficiencies on the company&#8217;s medium-term margins.
Price Action: VERX shares are up 1.95% at $34.25 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44358669/energy-vault-strengthens-australian-presence-with-220-million-acquisition-of-stoney-creek" target="_blank" rel="noreferrer noopener">Energy Vault Strengthens Australian Presence With Stoney Creek Deal: Details</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Mid Cap

Price Target

VERX

Goldman Sachs Analyst Anticipates Clarity On Vertex's Investment Roadmap And Product Monetization At Investor Day

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs cut Bumble Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NYSE">BMBL</a>) price target from $10 to $8. Goldman Sachs analyst Alexandra Steiger maintained a Buy rating. Bumble shares closed at $4.82 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BMBL/analyst-ratings">view this stock</a>.</li>
<li>Oppenheimer slashed the price target for Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) from $235 to $230. Oppenheimer analyst Jed Kelly maintained an Outperform rating. Expedia shares closed at $162.11 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/EXPE/analyst-ratings">view this stock</a>.</li>
<li>Morgan Stanley cut McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) price target from $340 to $335. Morgan Stanley analyst John Glass maintained an Overweight rating. McDonald&#8217;s shares closed at $299.83 on Friday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital raised the price target for Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) from $47 to $48. BMO Capital analyst Andrew Strelzik maintained a Market Perform rating. Pilgrim&#8217;s Pride shares closed at $49.62 on Friday. <a href="https://www.benzinga.com/quote/PPC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) from $121 to $115. JP Morgan analyst Philip Cusick maintained a Neutral rating. Crown Castle shares closed at $103.22 on Thursday. See how other analysts view <a href="https://www.benzinga.com/quote/CCI/analyst-ratings">this stock</a>.</li>
<li>Scotiabank cut Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) price target from $85 to $75. Scotiabank analyst Allan Verkhovski maintained a Sector Perform rating. Zoom shares settled at $74.20 on Friday. <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson cut e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) price target from $80 to $75. DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating. e.l.f. Beauty shares closed at $68.18 on Friday. <a href="https://www.benzinga.com/quote/ELF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS cut Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) price target from $74 to $50. UBS analyst Timothy Arcuri maintained a Neutral rating. Western Digital shares closed at $44.53 on Friday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho cut the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $515 to $430. Mizuho analyst Vijay Rakesh maintained an Outperform rating. Tesla shares settled at $249.98 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham slashed NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $84 to $80. Needham analyst Tom Nikic maintained a Buy rating. Nike shares closed at $71.66 on Friday. <a href="https://www.benzinga.com/quote/nke/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? 
<ul>
<li> <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

BMBL

EXPE

Tesla To $430? Here Are 10 Top Analyst Forecasts For Monday

WIIM

ARQT

Arcutis Biotherapeutics shares are trading higher after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis.

Needham analyst Bernie McTernan reiterated a <a target="_blank" href="https://www.benzinga.com/quote/APP/analyst-ratings" rel="noreferrer noopener">Hold rating </a>on the shares of AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>).
The analyst has introduced initial APP Ecommerce Tracker to assess APP&#8217;s expansion beyond mobile gaming ads into industries like ecommerce.
After reviewing over 2,200 ecommerce sites, the analyst found 297 working with APP, which represents about 50% of the 600 brands APP reported in December.
The most common industries include health &amp; personal care, apparel, and furniture. Notable advertisers include W, Marine Layer, Bombas, and others. The tracker will be updated regularly to monitor new brands and potential self-service launches, said the analyst.
The analyst examined over 2,200 ecommerce websites for the Axon pixel, which indicates a partnership with APP for advertising. The pixel tracks user interactions from ads to websites.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44356299/why-is-clothing-firm-guess-stock-surging-today" rel="noreferrer noopener">Why Is Clothing Firm Guess Stock Surging Today?</a>
The analyst found 297 websites with the pixel, aligning with APP&#8217;s reported 600 advertisers by the end of 2024. The websites were categorized by product type and are also monitoring 60 major brands that could become significant advertisers on the platform.
APP is working with a diverse range of product categories, with over 40% of the websites in the Health &amp; Personal Care sector, a significant category in U.S. retail ecommerce.
Apparel, footwear, and accessories make up 25% of the websites tracked. This broad category representation underscores the potential for large advertising spend and highlights the vast market opportunity for APP's new venture.
While most of the 2,200 websites in the survey are smaller DTC products, 60 major brands like Nike, Amazon, and Etsy are key to tracking, as they could significantly boost advertising revenue for APP. From this list, only Wayfair was found to have the APP pixel installed, noted the analyst.
According to the analyst, AppLovin is poised to benefit from the growing shift toward in-app advertising (IAA) and the increasing importance of first-party consumer data.
The company has developed the tools and data to help software clients drive user acquisition and monetize ads. With changing user preferences and advertiser focus on first-party data, there is significant growth potential in in-app advertising, especially within casual gaming apps.
Price Action: APP shares traded higher by 4.82% at $307.02 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44355290/why-is-chinese-ev-charging-provider-naas-technologys-stock-surging-today" target="_blank" rel="noreferrer noopener">Why Is Chinese EV Charging Provider NaaS Technology&#8217;s Stock Surging Today?</a></li>
</ul>
Image via Shutterstock.

AppLovin Taps Into Retail Ad Market, But Growth Hinges On Big-Brand Adoption: Analyst

Pliant Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>)&nbsp;released on Monday data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation trial of PLN-101095, in combination with Merck &amp; Co Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab), in patients with immune checkpoint inhibitor (ICI)-refractory advanced or <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">metastatic solid tumors</a>.
Interim results demonstrated PLN-101095 antitumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily (BID) dose, representing a 50% objective response rate (ORR) at the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44353808/pliant-therapeutics-announces-interim-phase-1-data-for-pln-101095-in-patients-with-immune-checkpoi" rel="noreferrer noopener">highest dose tested to date</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44120576/pliant-therapeutics-drops-ipf-drug-trial-after-review-analyst-flags-uncertain-future" rel="noreferrer noopener">Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future</a>
PLN-101095 was generally well tolerated across all doses tested.
Nine patients with six different tumor types were enrolled in cohorts one through three of the trial.
Patients were treated for 14 days with PLN-101095 at doses of 250 mg, 500 mg or 1000 mg administered orally BID, followed by treatment with a combination of PLN-101095 and pembrolizumab at 200 mg administered intravenously every three weeks (Q3W):&nbsp;
<ul>
<li>Across all doses tested, PLN-101095 was generally well tolerated.</li>
<li>Of the six patients treated at the 1000 mg BID dose of PLN-101095, three (50%) confirmed partial responses were observed. All three patients remain on treatment.
<ul>
<li>Non-Small Cell Lung Cancer (NSCLC):&nbsp;Confirmed partial response with a 74% reduction in tumor size at Week 18; initial partial response was observed at Week 10.</li>
<li>Cholangiocarcinoma: Confirmed partial response with a 48% reduction in tumor size at Week 42; initial partial response was observed at Week 34.</li>
<li>Melanoma: Confirmed partial response with a 42% reduction in tumor size at Week 27; initial partial response was observed at Week 18.</li>
</ul>
</li>
</ul>
The Phase 1 trial of PLN-101095 is currently enrolling the fourth of five potential cohorts. The fourth cohort is evaluating PLN-101095 at 1000 mg, three times daily (TID).
PLRX Price Action: Pliant Therapeutics stock is up 12.99% at $1.74 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44356299/why-is-clothing-firm-guess-stock-surging-today" target="_blank" rel="noreferrer noopener">Why Is Clothing Firm Guess Stock Surging Today?</a></li>
</ul>
Photo: Shutterstock

PLRX

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types

BofA Securities analyst Andrew Obin reiterated a Buy rating on Eaton Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with a price forecast of $410 following <a target="_blank" href="https://www.benzinga.com/quote/etn/analyst-ratings" rel="noreferrer noopener">last week&#8217;s investor day</a>.
The analyst writes that, at the event, the company issued 2024-2030 targets of organic growth of 6%-9% and adjusted EPS CAGR of over 12%, aligning with his expectations and investor forecasts.
Obin notes that while data centers contribute to organic growth (~19% of sales in 2025E; high-teens CAGR), growth is broad-based, with Commercial &amp; Institutional (20% of sales), Utilities (11%), and Aerospace (15%) also expected to grow at high-single-digit rates.
Eaton expects 350-450bps margin expansion by 2030 (~28% segment margins), driven mainly by Electrical Global and Aerospace. The guidance appears reasonable with potential upside, per the analyst.
The analyst estimates organic growth to accelerate on the margin from 2025 in 2026/2027, and decelerate in the outer years of the company&#8217;s target.
The analyst witnessed investor pushback that the implied returns from Eaton&#8217;s &gt;$1.5 billion in capacity additions are &#8216;too high.&#8217;
Meanwhile, Obin&#8217;s discussions with the company at the event suggest that the strong returns on incremental investments align with Eaton&#8217;s established framework.
The analyst raised estimates for 2026/2027 EPS to $13.43 (from $13.20) and $15.09 (from $14.35).
Price Action: ETN shares are up 2.00% at $299.49 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44245475/eaton-strengthens-data-center-strategy-with-14-billion-fibrebond-acquisition" target="_blank" rel="noreferrer noopener">Eaton Strengthens Data Center Strategy With $1.4 Billion Fibrebond Acquisition</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Eaton's Growth Targets Look Achievable, Analyst Raises EPS Forecast For 2026 & 2027

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$40.00</td>
<td>$27.0K</td>
<td>19.6K</td>
<td>12.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$41.00</td>
<td>$43.0K</td>
<td>10.4K</td>
<td>3.1K</td>
</tr>
<tr>
<td>SOFI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$11.00</td>
<td>$25.6K</td>
<td>3.9K</td>
<td>2.6K</td>
</tr>
<tr>
<td>CME</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$260.00</td>
<td>$104.4K</td>
<td>479</td>
<td>684</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$45.00</td>
<td>$34.9K</td>
<td>123</td>
<td>603</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$70.00</td>
<td>$73.0K</td>
<td>1.5K</td>
<td>445</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/11/25</td>
<td>$55.00</td>
<td>$28.5K</td>
<td>128</td>
<td>325</td>
</tr>
<tr>
<td>XYZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$47.50</td>
<td>$76.7K</td>
<td>1.7K</td>
<td>216</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$550.00</td>
<td>$25.4K</td>
<td>1.1K</td>
<td>114</td>
</tr>
<tr>
<td>MCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$450.00</td>
<td>$34.0K</td>
<td>54</td>
<td>86</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HOOD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $40.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $270.0 per contract. There were 19685 open contracts at this strike prior to today, and today 12007 contract(s) were bought and sold. 
• Regarding BAC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), we observe a call option trade with neutral sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 500 contract(s) at a $41.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $86.0 per contract. There were 10410 open contracts at this strike prior to today, and today 3104 contract(s) were bought and sold. 
• For SOFI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), we notice a put option trade that happens to be bearish, expiring in 11 day(s) on March 28, 2025. This event was a transfer of 1600 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $16.0 per contract. There were 3974 open contracts at this strike prior to today, and today 2660 contract(s) were bought and sold. 
• For CME (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), we notice a put option trade that happens to be bearish, expiring in 186 day(s) on September 19, 2025. This event was a transfer of 81 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $104.4K, with a price of $1290.0 per contract. There were 479 open contracts at this strike prior to today, and today 684 contract(s) were bought and sold. 
• Regarding AFRM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on March 28, 2025. Parties traded 167 contract(s) at a $45.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $34.9K, with a price of $209.0 per contract. There were 123 open contracts at this strike prior to today, and today 603 contract(s) were bought and sold. 
• Regarding C (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), we observe a call option trade with bullish sentiment. It expires in 60 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $73.0K, with a price of $365.0 per contract. There were 1569 open contracts at this strike prior to today, and today 445 contract(s) were bought and sold. 
• Regarding UPST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>), we observe a call option trade with neutral sentiment. It expires in 25 day(s) on April 11, 2025. Parties traded 100 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $285.0 per contract. There were 128 open contracts at this strike prior to today, and today 325 contract(s) were bought and sold. 
• Regarding XYZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), we observe a put option sweep with bullish sentiment. It expires in 186 day(s) on September 19, 2025. Parties traded 216 contract(s) at a $47.50 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $76.7K, with a price of $355.0 per contract. There were 1740 open contracts at this strike prior to today, and today 216 contract(s) were bought and sold. 
• Regarding GS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), we observe a put option trade with bearish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 33 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $770.0 per contract. There were 1167 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• Regarding MCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>), we observe a put option sweep with neutral sentiment. It expires in 31 day(s) on April 17, 2025. Parties traded 31 contract(s) at a $450.00 strike. This particular put needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $1140.0 per contract. There were 54 open contracts at this strike prior to today, and today 86 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AFRM

HOOD

SOFI

UPST

10 Financials Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$250.00</td>
<td>$185.5K</td>
<td>13.7K</td>
<td>54.4K</td>
</tr>
<tr>
<td>AMZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$195.00</td>
<td>$40.2K</td>
<td>10.3K</td>
<td>10.9K</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$65.00</td>
<td>$85.0K</td>
<td>264</td>
<td>2.3K</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$149.00</td>
<td>$35.6K</td>
<td>2.1K</td>
<td>2.3K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.85</td>
<td>$30.4K</td>
<td>23.8K</td>
<td>766</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$85.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>410</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$175.00</td>
<td>$29.0K</td>
<td>573</td>
<td>295</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$120.00</td>
<td>$58.3K</td>
<td>424</td>
<td>69</td>
</tr>
<tr>
<td>SHAK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$90.00</td>
<td>$74.8K</td>
<td>85</td>
<td>62</td>
</tr>
<tr>
<td>HLT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$300.00</td>
<td>$26.4K</td>
<td>30</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 580 contract(s) at a $250.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $185.5K, with a price of $320.0 per contract. There were 13786 open contracts at this strike prior to today, and today 54443 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a put option sweep with neutral sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 156 contract(s) at a $195.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $40.2K, with a price of $258.0 per contract. There were 10383 open contracts at this strike prior to today, and today 10915 contract(s) were bought and sold. 
• Regarding NKE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $65.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $85.0K, with a price of $850.0 per contract. There were 264 open contracts at this strike prior to today, and today 2394 contract(s) were bought and sold. 
• Regarding BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 117 contract(s) at a $149.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $305.0 per contract. There were 2115 open contracts at this strike prior to today, and today 2337 contract(s) were bought and sold. 
• Regarding F (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), we observe a put option sweep with bearish sentiment. It expires in 186 day(s) on September 19, 2025. Parties traded 321 contract(s) at a $9.85 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $30.4K, with a price of $95.0 per contract. There were 23878 open contracts at this strike prior to today, and today 766 contract(s) were bought and sold. 
• Regarding WYNN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $85.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 1838 open contracts at this strike prior to today, and today 410 contract(s) were bought and sold. 
• For CVNA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on March 21, 2025. This event was a transfer of 20 contract(s) at a $175.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.0K, with a price of $1450.0 per contract. There were 573 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), we notice a put option trade that happens to be bearish, expiring in 305 day(s) on January 16, 2026. This event was a transfer of 13 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $58.3K, with a price of $4485.0 per contract. There were 424 open contracts at this strike prior to today, and today 69 contract(s) were bought and sold. 
• For SHAK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>), we notice a put option sweep that happens to be bearish, expiring in 186 day(s) on September 19, 2025. This event was a transfer of 58 contract(s) at a $90.00 strike. This particular put needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $74.8K, with a price of $1290.0 per contract. There were 85 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
• Regarding HLT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>), we observe a call option sweep with bearish sentiment. It expires in 305 day(s) on January 16, 2026. Parties traded 54 contract(s) at a $300.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $490.0 per contract. There were 30 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

BABA

CAVA

CVNA

SHAK

WYNN

10 Consumer Discretionary Stocks With Whale Alerts In Today's Session

ORCL

Oracle shares are trading higher after reports indicated the company is in talks with the White House to oversee the US operations of TikTok.

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$120.00</td>
<td>$82.8K</td>
<td>137.7K</td>
<td>82.5K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$85.00</td>
<td>$76.6K</td>
<td>11.4K</td>
<td>15.3K</td>
</tr>
<tr>
<td>BASE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.50</td>
<td>$34.6K</td>
<td>4.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$290.00</td>
<td>$167.0K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$26.00</td>
<td>$26.7K</td>
<td>17.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$185.00</td>
<td>$42.4K</td>
<td>908</td>
<td>839</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$135.00</td>
<td>$26.2K</td>
<td>13.2K</td>
<td>732</td>
</tr>
<tr>
<td>XRX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$68.0K</td>
<td>20.1K</td>
<td>685</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$185.00</td>
<td>$249.0K</td>
<td>20</td>
<td>665</td>
</tr>
<tr>
<td>ZM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$75.00</td>
<td>$143.4K</td>
<td>4.6K</td>
<td>300</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 255 contract(s) at a $120.00 strike. This particular call needed to be split into 43 different trades to become filled. The total cost received by the writing party (or parties) was $82.8K, with a price of $325.0 per contract. There were 137772 open contracts at this strike prior to today, and today 82502 contract(s) were bought and sold. 
• For PLTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), we notice a put option trade that happens to be bullish, expiring in 4 day(s) on March 21, 2025. This event was a transfer of 286 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $76.6K, with a price of $268.0 per contract. There were 11413 open contracts at this strike prior to today, and today 15332 contract(s) were bought and sold. 
• Regarding BASE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on March 21, 2025. Parties traded 330 contract(s) at a $12.50 strike. This particular call needed to be split into 32 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $105.0 per contract. There were 4009 open contracts at this strike prior to today, and today 1491 contract(s) were bought and sold. 
• Regarding MSTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on March 28, 2025. Parties traded 100 contract(s) at a $290.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $167.0K, with a price of $1670.0 per contract. There were 1058 open contracts at this strike prior to today, and today 1070 contract(s) were bought and sold. 
• For INTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), we notice a call option trade that happens to be bullish, expiring in 60 day(s) on May 16, 2025. This event was a transfer of 103 contract(s) at a $26.00 strike. The total cost received by the writing party (or parties) was $26.7K, with a price of $260.0 per contract. There were 17252 open contracts at this strike prior to today, and today 1032 contract(s) were bought and sold. 
• For MSFT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), we notice a call option trade that happens to be bullish, expiring in 458 day(s) on June 18, 2026. This event was a transfer of 2 contract(s) at a $185.00 strike. The total cost received by the writing party (or parties) was $42.4K, with a price of $21200.0 per contract. There were 908 open contracts at this strike prior to today, and today 839 contract(s) were bought and sold. 
• Regarding TSM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), we observe a put option sweep with bullish sentiment. It expires in 95 day(s) on June 20, 2025. Parties traded 114 contract(s) at a $135.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $230.0 per contract. There were 13263 open contracts at this strike prior to today, and today 732 contract(s) were bought and sold. 
• For XRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>), we notice a put option trade that happens to be bearish, expiring in 305 day(s) on January 16, 2026. This event was a transfer of 680 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $68.0K, with a price of $100.0 per contract. There were 20111 open contracts at this strike prior to today, and today 685 contract(s) were bought and sold. 
• For AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we notice a call option trade that happens to be bearish, expiring in 1005 day(s) on December 17, 2027. This event was a transfer of 40 contract(s) at a $185.00 strike. The total cost received by the writing party (or parties) was $249.0K, with a price of $6225.0 per contract. There were 20 open contracts at this strike prior to today, and today 665 contract(s) were bought and sold. 
• Regarding ZM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>), we observe a put option trade with neutral sentiment. It expires in 95 day(s) on June 20, 2025. Parties traded 300 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $143.4K, with a price of $478.0 per contract. There were 4621 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

BASE

MSFT

MSTR

NVDA

PLTR

10 Information Technology Stocks With Whale Alerts In Today's Session

Rivian Automotive Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock officially entered <a href="https://www.benzinga.com/topic/death-cross">a Death Cross</a>, a bearish technical signal that occurs when the 50-day simple moving average (SMA) drops below the 200-day SMA.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="618" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17125517/Screenshot-2025-03-17-at-5.12.06-PM.png" alt="" class="wp-image-827771" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17125517/Screenshot-2025-03-17-at-5.12.06-PM.png 618w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17125517/Screenshot-2025-03-17-at-5.12.06-PM-300x236.png 300w" sizes="(max-width: 618px) 100vw, 618px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
This pattern often indicates sustained downside momentum, and with Rivian stock already down nearly 18% year to date and over 24% in the past month, the technical outlook isn't encouraging.
Read Also: <a href="https://www.benzinga.com//node/44136503">Rivian&#8217;s Georgia Facility To Be Ready In 2028, EV Exports To Foreign Markets After R2 Production Ramp, Says CFO</a>
<h1 class="wp-block-heading">Rivian Stock's Death Cross Signals A Steeper Decline</h1>
The numbers confirm Rivian stock's bearish trajectory:
<ul>
<li>Death Cross Formation: The 50-day SMA ($12.70) has crossed below the 200-day SMA ($12.73), a historically bearish indicator.</li>
<li>Moving Averages: Rivian stock, at $10.74, is trading below its eight-day ($10.89), 20-day ($11.72), 50-day ($12.70), and 200-day ($12.73) SMAs, reinforcing downward pressure.</li>
<li>Moving Average Convergence Divergence (MACD): The MACD indicator at a negative 0.58 suggests weak momentum, a sign that sellers remain in control.</li>
<li>Relative Strength Index (RSI): At 37.12, the RSI is approaching oversold territory but hasn't yet signaled a reversal.</li>
</ul>
With these technicals aligning in a bearish pattern, traders may remain cautious until a bullish catalyst emerges.
<h1 class="wp-block-heading">Investor Implications: More Downside Possible?</h1>
The death cross often leads to extended weakness, particularly in a stock already struggling with declining momentum. 
While Rivian's plans to ramp up production of its R2 SUV in 2026 and expand internationally could support long-term growth, short-term traders may see further downside risk.
For now, Rivian&#8217;s stock is in a downtrend, and technical traders might wait for signs of a reversal before considering a bullish stance. Until then, the death cross remains a clear warning signal for investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44360400/legendary-trader-says-tesla-nvidia-apple-shares-are-ready-to-rally-i-see-what-i-like-to-see">Legendary Trader Says Tesla, Nvidia, Apple Shares Are Ready To Rally: &#8216;I See What I Like To See&#8217;</a></li>
</ul>
Photo: Shutterstock

RIVN

Rivian's Bearish Breakdown: Death Cross Confirms Downtrend

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) ("Better Choice" or the "Company"), a pet health and wellness company, today announced that its Board of Directors have approved a significant royalty distribution plan for shareholders. Under this new initiative, up to 55% of the annual royalties generated by the Company's flagship Halo brand will be distributed annually to stockholders of record as of December 31 of the given year. The aggregate amount and other details of each such distribution shall be determined by the Company's Board of Directors on an annual basis, and the declaration of each such distribution will be effected by appropriate Board action at such time.

Dividends

BTTR

Better Choice Company Has Approved A Significant Royalty Distribution Plan For Shareholders; Up To 55% Of The Annual Royalties Generated By The Company's Flagship Halo Brand Will Be Distributed Annually To Stockholders Of Record As Of December 31 Of The Given Year

CLMT

GEVO

MPLX

NCSM

NEHC

OPAL

Shares of oil and gas companies are trading higher amid weakness in the dollar after the US launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting the demand outlook.

Oil is trading higher amid weakness in the dollar and after the US launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting demand outlook.

Press Releases

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Comments

Repare Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌